| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
| Targets |
iNOS; COX-2; NF-κB
|
|---|---|
| ln Vitro |
Hederagenin could induce apoptosis of LoVo cells through the mitochondrial apoptotic pathway. Hederagenin may cause procaspase-9, procaspase-3, and proPARP cleavage in addition to the up-regulation of Bax and the down-regulation of Bcl-2, Bcl-xL, and Survivin[1]. In LPS-induced RAW264.7 cells, hederagenin inhibits the pathways of NF-B, which results in a decrease in the production of pro-inflammatory mediators (NO, PGE2, TNF-α, IL-1β, and IL-6)[2].
|
| ln Vivo |
In NCI-H1299 xenograft mice, hederin alone (25 mg/kg; p.o.; 11 days) had no effect on tumor growth. When combined with cisplatin (1 mg/kg), it inhibits tumor growth in a synergistic manner [4]. In mice, hederagenin (50 mg/kg; oral; once daily for 21 days) decreases 25% ethanol-induced liver damage and has anti-inflammatory and anti-apoptotic effects [5].
|
| Cell Assay |
At a density of 10,000 cells per well, LoVo cells are seeded into 96-well plates. The medium is discarded and then treated with 20 μl MTT (5 mg/ml) after having been exposed to 0.25, 0.5, 1.0, 2.0, and 4.0 M hederagenin for 24 or 48 hours. The 100 μl DMSO is added to each well after the incubation period of 4 h at 37°C in order to dissolve the formed formazan crystals. At 490 nm, absorption is discovered.
|
| References |
[1]. Su-Hong Lu et al. Experimental Study of Antiatherosclerosis Effects with Hederagenin in Rats. Evid Based Complement Alternat Med, 2015, Oct 19
[2]. Diego Rodríguez-Hernández et al. Hederagenin as a triterpene template for the development of new antitumor compounds. Eur J Med Chem, 2015 Nov 13, 105:57-62 [3]. Chul Won Lee et al. Hederagenin, a major component of Clematis mandshurica Ruprecht root, attenuates inflammatory responses in RAW 264.7 cells and in mice. Int Immunopharmacol, 2015 Dec, 29(2):528-37. |
| Molecular Formula |
C30H48O4
|
|---|---|
| Molecular Weight |
472.71
|
| Exact Mass |
472.3553
|
| Elemental Analysis |
C, 76.23; H, 10.24; O, 13.54
|
| CAS # |
465-99-6
|
| Related CAS # |
465-99-6
|
| Appearance |
Solid powder
|
| SMILES |
C[C@]12CC[C@@H]([C@@]([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)CO)O
|
| InChi Key |
PGOYMURMZNDHNS-MYPRUECHSA-N
|
| InChi Code |
InChI=1S/C30H48O4/c1-25(2)13-15-30(24(33)34)16-14-28(5)19(20(30)17-25)7-8-22-26(3)11-10-23(32)27(4,18-31)21(26)9-12-29(22,28)6/h7,20-23,31-32H,8-18H2,1-6H3,(H,33,34)/t20-,21+,22+,23-,26-,27-,28+,29+,30-/m0/s1
|
| Chemical Name |
(4aS,6aR,6aS,6bR,8aR,9R,10S,12aR,14bS)-10-hydroxy-9-(hydroxymethyl)-2,2,6a,6b,9,12a-hexamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| Synonyms |
Astrantiagenin E; Hederagenin; Hederagenol; NSC 24954; Caulosapogenin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50~94 mg/mL (105.8~198.9 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.29 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.29 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1155 mL | 10.5773 mL | 21.1546 mL | |
| 5 mM | 0.4231 mL | 2.1155 mL | 4.2309 mL | |
| 10 mM | 0.2115 mL | 1.0577 mL | 2.1155 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
